FAIRFIELD, Conn., March 11, 2011 (GLOBE NEWSWIRE) -- Competitive Technologies, Inc. (OTCQX:CTTC) today announced that researchers at the University of Wisconsin's Carbone Cancer Center have begun accepting patients into a new Phase II clinical study to evaluate the efficacy of the innovative Calmare® Pain Therapy medical device utilizing Scrambler Technology versus a sham procedure in treating painful chemotherapy-induced peripheral neuropathy (CIPN). The principal investigator for this study is Toby C. Campbell, M.D., who is a research physician specializing in medical oncology and palliative care at the University of Wisconsin Carbone Cancer Center.
The study designed by Dr. Campbell is a randomized double-blind, sham-controlled clinical trial with a target enrollment of 40 patients. The study will measure the effectiveness of the devices by recording the change in participants pain as measured by a Visual Analog Scale (VAS) before and after treatment with the Calmare® Scrambler MC-5A device or the sham device.
About University of Wisconsin Carbone Cancer Center
The University of Wisconsin Carbone Cancer Center is recognized throughout the Midwest and the nation as one of the leading innovators in cancer research, quality patient care and active community involvement. UW Carbone Cancer Center is the only comprehensive cancer center, as designated by the National Cancer Institute, in Wisconsin. An integral part of the UW School of Medicine and Public Health, the UW Carbone Cancer Center unites more than 250 physicians and scientists who work together in translating discoveries from research laboratories into new treatments that benefit cancer patients. Learn more about this and other clinical studies and other initiatives at the UW Carbone Cancer Center Research and Health Professionals Site at http://www.cancer.wisc.edu.
About Competitive Technologies
Competitive Technologies, established in 1968, provides distribution, patent and technology transfer, sales and licensing services focused on the needs of its customers, and matching those requirements with commercially viable product or technology solutions. CTTC is a global leader in identifying, developing and commercializing innovative products and technologies. CTTC's principal technology is the non-invasive Calmare® Pain Therapy medical device, which uses the biophysical "Scrambler Therapy" technology, and was developed in Italy by CTTC's client, Professor Giuseppe Marineo. The Calmare® device is currently being manufactured for sale by CTTC's partner, GEOMC Co., Ltd. of Seoul, Korea. For more information on the device, visit www.calmarett.com. Visit CTTC's website: www.competitivetech.net.
Statements made about our future expectations are forward-looking statements and subject to risks and uncertainties as described in our most recent Annual Report on Form 10-K for the year ended July 31, 2010, filed with the SEC on October 27, 2010, and other filings with the SEC, and are subject to change at any time. Our actual results could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking statement.